Loading...
XJPX4538
Market cap136mUSD
Jan 15, Last price  
2,490.00JPY
1D
2.13%
1Q
4.97%
Jan 2017
-10.53%
Name

Fuso Pharmaceutical Industries Ltd

Chart & Performance

D1W1MN
XJPX:4538 chart
P/E
15.45
P/S
0.38
EPS
161.19
Div Yield, %
3.03%
Shrs. gr., 5y
-0.38%
Rev. gr., 5y
3.76%
Revenues
55.41b
+8.61%
41,938,000,00042,672,000,00043,169,000,00043,991,000,00045,901,000,00046,560,000,00047,469,000,00044,358,000,00048,612,000,00049,100,000,00047,042,000,00045,752,000,00046,781,000,00045,900,000,00046,073,000,00046,901,000,00049,253,000,00049,632,000,00051,015,000,00055,406,000,000
Net income
1.38b
-14.21%
582,000,000-1,929,000,000-2,038,000,000107,000,000-931,000,000518,000,0001,144,000,000372,000,0004,871,000,0001,979,000,000340,000,00010,000,000861,000,000970,000,000894,000,000707,000,0001,607,000,0001,483,000,0001,605,000,0001,377,000,000
CFO
627m
-78.02%
1,179,000,0003,353,000,0001,615,000,0001,987,000,0001,183,000,0002,186,000,0006,944,000,000884,000,0003,258,000,0002,889,000,0001,943,000,0002,117,000,0001,876,000,0001,420,000,0002,051,000,0005,726,000,0003,230,000,0003,498,000,0002,853,000,000627,000,000
Dividend
Mar 28, 20250 JPY/sh

Profile

Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.
URL
https://www.fuso-pharm.co.jp/
IPO date
Dec 22, 1989
Employees
1,370
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
55,406,000
8.61%
51,015,000
2.79%
49,632,000
0.77%
Cost of revenue
43,358,000
38,627,000
37,677,000
Unusual Expense (Income)
NOPBT
12,048,000
12,388,000
11,955,000
NOPBT Margin
21.74%
24.28%
24.09%
Operating Taxes
389,000
599,000
427,000
Tax Rate
3.23%
4.84%
3.57%
NOPAT
11,659,000
11,789,000
11,528,000
Net income
1,377,000
-14.21%
1,605,000
8.23%
1,483,000
-7.72%
Dividends
(645,000)
(525,000)
(525,000)
Dividend yield
3.40%
3.00%
2.74%
Proceeds from repurchase of equity
(652,000)
3,532,000
2,887,000
BB yield
3.44%
-20.17%
-15.06%
Debt
Debt current
5,701,000
6,885,000
6,334,000
Long-term debt
7,021,000
5,747,000
5,759,000
Deferred revenue
1,155,000
1,228,000
Other long-term liabilities
1,150,000
126,000
127,000
Net debt
3,678,000
1,448,000
1,512,000
Cash flow
Cash from operating activities
627,000
2,853,000
3,498,000
CAPEX
(3,588,000)
(1,574,000)
(1,487,000)
Cash from investing activities
(3,536,000)
(1,373,000)
(1,553,000)
Cash from financing activities
14,000
(813,000)
(1,671,000)
FCF
8,463,000
10,601,000
12,230,000
Balance
Cash
5,120,000
8,014,000
7,347,000
Long term investments
3,924,000
3,170,000
3,234,000
Excess cash
6,273,700
8,633,250
8,099,400
Stockholders' equity
21,999,000
22,813,000
21,692,000
Invested Capital
43,606,300
40,502,750
39,741,600
ROIC
27.72%
29.38%
29.05%
ROCE
23.23%
24.55%
24.32%
EV
Common stock shares outstanding
8,611
8,771
8,772
Price
2,201.00
10.27%
1,996.00
-8.69%
2,186.00
-14.11%
Market cap
18,951,860
8.25%
17,507,054
-8.70%
19,176,351
-14.12%
EV
22,629,860
18,955,054
20,688,351
EBITDA
14,311,000
14,874,000
14,514,000
EV/EBITDA
1.58
1.27
1.43
Interest
171,000
165,000
176,000
Interest/NOPBT
1.42%
1.33%
1.47%